Press release
Keros Therapeutics to Present at the 63rd American Society of Hematology Annual Meeting and Exposition, Including Presenting Additional Data from its Phase 2 Clinical Trial Evaluating KER-050 in Patients with Myelodysplastic Syndromes
LEXINGTON, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on
About this update from Keros Therapeutics, Inc.
[{"type":"text","content":"LEXINGTON, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today announced that four abstracts will be presented from the KER-050 and ALK2 hematology programs, including additional preliminary results from Keros’ Phase 2 clinical trial of KER-050 in patients with very low-, low-, or intermediate-risk myelodysplastic syndromes (“MDS”), at the 63rd American Society of Hematology (“ASH”) Annual Meeting and Exposition, to be held in person and virtually from December 11 through 14, 2021. The following abstracts were posted to the ASH website on November 4, 2021, 9:00 a.m. Eastern time. Clinical Presentation “A Phase 2, Open-Label, Ascending Dose Study of KER-050 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes” Publication Number: 3675Session Name: 637. Myelodysplastic Syndromes — Clinical and Epidemiological: Poster IIIDate: Monday, December 13, 2021Presentation Time: 6:00 p.m. - 8:00 p.m. Eastern time Preclinical Presentations “KER-050, an Inhibitor of TGF-β Superfamily Signaling, Promoted Thrombopoiesis and Reversed Immune Thrombocytopenia in a Mouse Model of Disease” Publication Number: 2068Session Name: 301. Vasculature, Endothelial Cells and Platelets: Basic and Translational: Poster IIDate: Sunday, December 12, 2021Presentation Time: 6:00 p.m. - 8:00 p.m. Eastern time “RKER-050 Rescued Ruxolitinib (Rux)-Associated Reductions in Red Blood Cell Volume” Publication Number: 934Session Name: 101. Red Cells and Erythropoiesis, Excluding Iron: Poster IDate: Saturday, December 11, 2021Presentation Time: 5:30 p.m. - 7:30 p.m. Eastern time “A Monoclonal Antibody Targeting ALK2 as a Potential Therapeutic Agent for Anemia of Inflammation” Publication Number: 2007Session Name: 102. Iron Homeostasis and Biology: Poster IIDate: Sunday, December 12, 2021Presentation Time: 6:00 p.m. - 8:00 p.m. Eastern time About KER-050 Keros’ lead protein therapeutic product candidate, KER-050, is an engineered ligand trap comprised of a modified ligand-binding domain of the Transforming Growth Factor-Beta receptor known as activin rece...